FDA panel narrowly votes to modify Avandia restrictions

Reuters: A narrowly divided U.S. Food and Drug Administration panel of outside experts on Thursday voted to modify market restrictions on GlaxoSmithKline's diabetes drug Avandia, the one-time blockbuster at the center of one of the biggest drug controversies in recent years.

Read article

i360Gov Newsletters

The most significant government policy, business, and technology news and analysis delivered to your inbox.

Subscribe Now

Trending